A new analysis of data from the SELECT trial shows that semaglutide, a GLP-1 receptor agonist, provides a clear cardiovascular protective effect in people with overweight or obesity and already established cardiovascular disease, even when they do not have diabetes
Sep 2014;22(1):209-221
With a focus on medical aesthetics and wellness, they have an established presence in Seattle
For there to be cost-effectiveness in saving money on claims related to cardiovascular disease, these drugs for weight loss should be priced at $7,500 to $9,800 annually
No patients receiving GLP-1 RAs were excluded due to loss of follow-up, while 8 patients (0.2%) who did not receive GLP-1 RAs were excluded for this reason (Supplemental Table 3)
If youd have trouble managing this alongside your busy lifestyle, consider injections